Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Catherine Weil-Olivier, Muhamed-Kheir Taha, Stéphane Bouée, Corinne Emery, Véronique Loncle-Provot, Gaëlle Nachbaur, Ekkehard Beck & Céline Pribil. (2022) Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Human Vaccines & Immunotherapeutics 18:1.
Read now
Read now
Nina Gustafsson, Sandra Elkjær Stallknecht, Mette Skovdal, Peter Bo Poulsen & Lars Østergaard. (2018) Societal costs due to meningococcal disease: a national registry-based study. ClinicoEconomics and Outcomes Research 10, pages 563-572.
Read now
Read now
Giannina Izquierdo, Juan Pablo Torres, M Elena Santolaya, M Teresa Valenzuela, Jeannette Vega & May Chomali. (2015) Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country. Human Vaccines & Immunotherapeutics 11:4, pages 875-883.
Read now
Read now
Maneesha Mehra, Ying Wu & Ravinder Dhawan. (2012) Healthcare resource use in advanced prostate cancer patients treated with docetaxel. Journal of Medical Economics 15:5, pages 836-843.
Read now
Read now
Articles from other publishers (17)
Catherine Weil-Olivier, Muhamed-Kheir Taha, Corinne Emery, Stéphane Bouée, Ekkehard Beck, Emmanuel Aris, Véronique Loncle-Provot, Gaëlle Nachbaur & Céline Pribil. (2021) Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database. Infectious Diseases and Therapy 10:3, pages 1607-1623.
Crossref
Crossref
Lucy Deng, Belinda Barton, Jennifer Lorenzo, Harunor Rashid, Fereshteh Dastouri & Robert Booy. (2021) Longer term outcomes following serogroup B invasive meningococcal disease. Journal of Paediatrics and Child Health 57:6, pages 894-902.
Crossref
Crossref
Grace S. Chung & David W. Hutton. (2020) Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry. PLOS ONE 15:10, pages e0239926.
Crossref
Crossref
Andrew Stawasz, Liping Huang, Paige Kirby & David Bloom. (2020) Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits. Frontiers in Public Health 8.
Crossref
Crossref
Emily C. Lawler. (2020) Giving Teens a Boost?. American Journal of Health Economics 6:2, pages 251-287.
Crossref
Crossref
Bing Wang, Hossein Haji Ali Afzali, Lynne Giles & Helen Marshall. (2019) Lifetime costs of invasive meningococcal disease: A Markov model approach. Vaccine 37:46, pages 6885-6893.
Crossref
Crossref
Joan M Balada-Llasat, Ning Rosenthal, Rodrigo Hasbun, Louise Zimmer, Samuel Bozzette, Steven Duff, Jessica Chung & Christine C. Ginocchio. (2019) Cost of managing meningitis and encephalitis among infants and children in the United States. Diagnostic Microbiology and Infectious Disease 93:4, pages 349-354.
Crossref
Crossref
Corwin A. Robertson, James Hedrick, Ehab Bassily & David P. Greenberg. (2019) Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D). Vaccine 37:8, pages 1016-1020.
Crossref
Crossref
Bing Wang, Renee Santoreneos, Hossein Afzali, Lynne Giles & Helen Marshall. (2018) Costs of Invasive Meningococcal Disease: A Global Systematic Review. PharmacoEconomics 36:10, pages 1201-1222.
Crossref
Crossref
Steve Duff, Rodrigo Hasbun, Christine C Ginocchio, Joan-Miquel Balada-Llasat, Louise Zimmer & Samuel A Bozzette. (2018) Economic analysis of rapid multiplex polymerase chain reaction testing for meningitis/encephalitis in pediatric patients. Future Microbiology 13:6, pages 617-629.
Crossref
Crossref
David A. Johnson, David Lieberman, John M. Inadomi, Uri Ladabaum, Richard C. Becker, Seth A. Gross, Kristin L. Hood, Susan Kushins, Mark Pochapin & Douglas J. Robertson. (2017) Increased Post-procedural Non-gastrointestinal Adverse Events After Outpatient Colonoscopy in High-risk Patients. Clinical Gastroenterology and Hepatology 15:6, pages 883-891.e9.
Crossref
Crossref
Federico Martinón-Torres. (2016) Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements. Journal of Adolescent Health 59:2, pages S12-S20.
Crossref
Crossref
Kevin Wymer, Beth A. Plunkett & Sangtae Park. (2015) Urolithiasis in pregnancy: a cost-effectiveness analysis of ureteroscopic management vs ureteral stenting. American Journal of Obstetrics and Gynecology 213:5, pages 691.e1-691.e8.
Crossref
Crossref
Bing Wang, Hossein Haji Ali Afzali & Helen Marshall. (2014) The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine 32:37, pages 4791-4798.
Crossref
Crossref
George Mathew & Zoran Obradovic. (2013) Dynamic distributed predictive learning models that preserve privacy for hospitals with insufficient labeled data. Network Modeling Analysis in Health Informatics and Bioinformatics 2:4, pages 245-255.
Crossref
Crossref
J. Zeidler, A. Lange, S. Braun, R. Linder, S. Engel, F. Verheyen & J.-M. Graf von der Schulenburg. (2013) Die Berechnung indikationsspezifischer Kosten bei GKV-Routinedatenanalysen am Beispiel von ADHSCalculation of disease-related costs in claims data analyses with the example of attention-deficit hyperactivity disorder. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 56:3, pages 430-438.
Crossref
Crossref
George Mathew & Zoran Obradovic. (2012) Distributed Privacy Preserving Decision Support System for Predicting Hospitalization Risk in Hospitals with Insufficient Data. Distributed Privacy Preserving Decision Support System for Predicting Hospitalization Risk in Hospitals with Insufficient Data.